Home›Trial›NCT06818812
🔬NCT06818812Phase 1ACTIVE NOT RECRUITING

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Study Summary

The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.

Conditions
Solid Tumors
Interventions / Drugs
INCB186748CetuximabGEMNabPmFOLFIRINOX
View on ClinicalTrials.gov ↗
Sponsor
INCY
Incyte Corporation
Oncology
C60/100
Study Details
Enrollment30 participants
Primary Completion—
Lead SponsorIncyte Corporation
Data Retrieved2026-04-11 02:55:29.647187+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.